These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 16083335)

  • 1. Novel therapeutic targets for Huntington's disease.
    Hannan AJ
    Expert Opin Ther Targets; 2005 Aug; 9(4):639-50. PubMed ID: 16083335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington's disease.
    Nithianantharajah J; Hannan AJ
    Neuroscience; 2013 Oct; 251():66-74. PubMed ID: 22633949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Huntington's disease: which drugs might help patients?
    Hannan AJ
    IDrugs; 2004 Apr; 7(4):351-8. PubMed ID: 15057641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synaptopathic mechanisms of neurodegeneration and dementia: Insights from Huntington's disease.
    Tyebji S; Hannan AJ
    Prog Neurobiol; 2017 Jun; 153():18-45. PubMed ID: 28377290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mediators, environmental modulators and experience-dependent synaptic dysfunction in Huntington's disease.
    Hannan AJ
    Acta Biochim Pol; 2004; 51(2):415-30. PubMed ID: 15218539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene-environment interactions, neuronal dysfunction and pathological plasticity in Huntington's disease.
    van Dellen A; Grote HE; Hannan AJ
    Clin Exp Pharmacol Physiol; 2005 Dec; 32(12):1007-19. PubMed ID: 16445565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early development of aberrant synaptic plasticity in a mouse model of Huntington's disease.
    Milnerwood AJ; Cummings DM; Dallérac GM; Brown JY; Vatsavayai SC; Hirst MC; Rezaie P; Murphy KP
    Hum Mol Genet; 2006 May; 15(10):1690-703. PubMed ID: 16600988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The therapeutic role of creatine in Huntington's disease.
    Ryu H; Rosas HD; Hersch SM; Ferrante RJ
    Pharmacol Ther; 2005 Nov; 108(2):193-207. PubMed ID: 16055197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Huntington disease. A review].
    Bonilla E
    Invest Clin; 2000 Jun; 41(2):117-41. PubMed ID: 10961047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The molecular biology of Huntington's disease.
    Ho LW; Carmichael J; Swartz J; Wyttenbach A; Rankin J; Rubinsztein DC
    Psychol Med; 2001 Jan; 31(1):3-14. PubMed ID: 11200958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic and environmental factors in the pathogenesis of Huntington's disease.
    van Dellen A; Hannan AJ
    Neurogenetics; 2004 Feb; 5(1):9-17. PubMed ID: 14745585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Huntington's Disease: Pathogenic Mechanisms and Therapeutic Targets.
    Wright DJ; Renoir T; Gray LJ; Hannan AJ
    Adv Neurobiol; 2017; 15():93-128. PubMed ID: 28674979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypothalamic and neuroendocrine changes in Huntington's disease.
    Hult S; Schultz K; Soylu R; Petersén A
    Curr Drug Targets; 2010 Oct; 11(10):1237-49. PubMed ID: 20594177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetics of Huntington's Disease.
    Bassi S; Tripathi T; Monziani A; Di Leva F; Biagioli M
    Adv Exp Med Biol; 2017; 978():277-299. PubMed ID: 28523552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weight loss in Huntington disease increases with higher CAG repeat number.
    Aziz NA; van der Burg JM; Landwehrmeyer GB; Brundin P; Stijnen T; ; Roos RA
    Neurology; 2008 Nov; 71(19):1506-13. PubMed ID: 18981372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delayed onset of Huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors.
    Glass M; van Dellen A; Blakemore C; Hannan AJ; Faull RL
    Neuroscience; 2004; 123(1):207-12. PubMed ID: 14667455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene-environment interactions modulating cognitive function and molecular correlates of synaptic plasticity in Huntington's disease transgenic mice.
    Nithianantharajah J; Barkus C; Murphy M; Hannan AJ
    Neurobiol Dis; 2008 Mar; 29(3):490-504. PubMed ID: 18165017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sirtuins as Modifiers of Huntington's Disease (HD) Pathology.
    Neo SH; Tang BL
    Prog Mol Biol Transl Sci; 2018; 154():105-145. PubMed ID: 29413175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysfunctional Dopaminergic Neurones in Mouse Models of Huntington's Disease: A Role for SK3 Channels.
    Dallérac GM; Levasseur G; Vatsavayai SC; Milnerwood AJ; Cummings DM; Kraev I; Huetz C; Evans KA; Walters SW; Rezaie P; Cho Y; Hirst MC; Murphy KP
    Neurodegener Dis; 2015; 15(2):93-108. PubMed ID: 25871323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective neuronal degeneration in Huntington's disease.
    Cowan CM; Raymond LA
    Curr Top Dev Biol; 2006; 75():25-71. PubMed ID: 16984809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.